PECAM1 and breast cancer: In a recent review (Fox et al, 2001), when studies on breast cancer with multivariate analysis that used antibodies to CD31 or CD34 were examined, most revealed a positive association with relapse free survival (RFS) (13 out of 14) and all for overall survival (OS) (12 out of 12).